The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
CORRECTION: Veeva Sys Q3 Adj $1.34 Beats $1.30 Estimate, Sales $616.50M Beat $615.82M Estimate
Veeva Sys (NYSE:VEEV) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.30 by 3.08…
Congressman Dave Joyce Will Introduce Bill To Reclassify State-Legal Cannabis At Federal Level
Republican Congressman Dave Joyce (OH-14) is leading the charge for marijuana legalization in the United States through the proposed STATES…
US Stock Futures Waver After 7-Week Winning Streak: Analyst Sees More Gains Piling Up On Dow’s Record Highs
U.S. stock futures indicate a cautious opening on Monday after the market’s seven consecutive weekly winning streak. As the time…